Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes

Blood

Volumn 98, Issue 3, 2001, Pages 558-564

  Ford, Anthony M ^a,b   Fasching, Karin ^a,b   Renate Panzer Gru E ^a,b   Koenig, Margit ^a,b   Haas, Oskar A ^a,b   Greaves, Mel F ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN TEL AML1; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; CANCER RECURRENCE; CASE REPORT; CLONE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE DELETION; GENE REARRANGEMENT; HUMAN; LEUKEMIA CELL; LEUKEMIA REMISSION; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; PRELEUKEMIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS;

EID: 0035437159     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.3.558     Document Type: Article

References (52)

1. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood. 1997;90:4243-4251.
2. Trueworthy R, Shuster J, Look T, et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol. 1992;10:606-613.
3. Shurtleff SA, Buijs A, Behm FG, at al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9:1985-1989.
4. Rubnitz JE, Shuster JJ, Land VJ, et al. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. Blood. 1997;89:1143-1146.
5. Maloney KW, McGavran L, Murphy JR, et al. TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification. Leukemia. 1999;13:1708-1712.
6. McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996;88:4252-4258.
7. Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood. 1997;90:4933-4937.
8. Loh ML, Silverman LB, Young ML, et al. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood. 1998;92:4792-4797.
9. Seeger K, Adams H-P, Buchwald D, et al. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. Blood. 1998;91:1716-1722.
10. Takahashi Y, Horibe K, Kiyoi H, et al. Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1998;20:190-195.
11. Zuna J, Hrusak O, Kalinová M, Muzíková K, Stary J, Trka J. TEL/AML1 positivity in childhood ALL: average or better prognosis? Leukemia. 1999;13:22-24.
12. Rubnitz JE, Behm FG, Wichlan D, et al. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia. 1999;13:19-21.
13. Seeger K, Buchwald D, Taube T, et al. TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood. Leukemia. 1999;13:1469-1470.
14. Chow CD, Dalla-Pozza L, Gottlieb DJ, Hertzberg MS. Two cases of very late relapsing childhood ALL carrying the TEL:AML1 fusion gene. Leukemia. 1999;13:1893-1899.
15. Goulden N, Langlands K, Steward C, Katz F, Potter M, Chessells J. PCR assessment of bone marrow status in "isolated" extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia. Br J Haematol. 1994;87:282-285.
16. Levasseur M, Maung ZT, Jackson GH, Kernahan J, Proctor SJ, Middleton PG. Relapse of acute lymphoblastic leukaemia 14 years after presentation: use of molecular techniques to confirm true re-emergency. Br J Haematol. 1994;87:437-438.
17. Frost L, Goodeve A, Wilson G, Peake I, Barker H, Vora A. Clonal stability in late-relapsing childhood lymphoblastic leukaemia. Br J Haematol. 1997;98:992-994.
18. Lo Nigro L, Cazzaniga G, Di Cataldo A, et al. Clonal stability in children with acute lymphoblastic leukemia (ALL) who relapsed five or more years after diagnosis. Leukemia. 1999;13:190-195.
19. Vora A, Frost L, Goodeve A, et al. Late relapsing childhood lymphoblastic leukemia. Blood. 1998;92:2334-2337.
20. Greaves M. Molecular genetics, natural history and the demise of childhood leukaemia. Eur J Cancer. 1999;35:173-185.
21. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999;354:1499-1503.
22. Ford AM, Bennett CA, Price CM, Bruin MCA, Van Wering ER, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci U S A. 1998;95:4584-4588.
23. Wiemels JL, Ford AM, Van Wering ER, Postma A, Greaves M. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood. 1999;94:1057-1062.
24. Romana SP, Le Coniat M, Poirel H, Marynen P, Bernard OA, Berger R. Deletion of the short arm of chromosome 12 is a secondary event in acute lymphoblastic leukemia with t(12;21). Leukemia. 1996;10:167-170.
25. Raynaud S, Cavé H, Baens M, et al. The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood. 1996;87:2891-2899.
26. Greaves MF. Aetiology of acute leukaemia. Lancet. 1997;349:344-349.
27. Schrappe M, Reiter A, Ludwig W-D, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95:3310-3322.
28. Baens M, Peeters P, Gu O-C, Aerssens J, Marynen P. Genomic organisation of TEL: the human ETS-variant gene 6. Genome Res. 1996;6:404-413.
29. Sacchi N, Magnani I, Kearney L, Wijsman J, Hagemeijer A, Darfler M. Interphase cytogenetics of the t(8;21)(q22;q22) associated with acute myelogenous leukemia by two-color fluorescence in situ hybridization. Cancer Genet Cytogenet. 1995;79:97-103.
30. Baccichet A, Sinnett D. Frequent deletion of chromosome 12p12.3 in children with acute lymphoblastic leukaemia. Br J Haematol. 1997;99:107-114.
31. Panzer-Grümayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95:790-794.
32. Szczepanski T, Pongers-Willemse MJ, Langerak AW, et al. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood. 1999;93:4079-4085.
33. Yokota S, Hansen-Hagge TE, Bartram CR. T-cell receptor delta gene recombination in common acute lymphoblastic leukemia: preferential usage of V delta 2 and frequent involvement of the J alpha cluster. Blood. 1991;77:141-148.
34. Avigad S, Kuperstein G, Zilberstein J, et al. TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia. Leukemia. 1999;13:481-483.
35. Chessells JM, Relapsed lymphoblastic leukaemia in children: a continuing challenge. Br J Haematol. 1998;102:423-438.
36. Yotnda P, Garcia F, Peuchmaur M, et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest. 1998;102:455-462.
37. Bradstock KF, Gootlieb DJ. Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Leuk Lymphoma. 1995;18:1-16.
38. Wiemels JL, Greaves M. Structure and possible mechanisms of TEL-AML1 gene fusions in childhood acute lymphoblastic leukemia. Cancer Res. 1999;59:4075-4082.
39. Takeuchi S, Seriu T, Tasaka T, et al. Microsatellite instability and other molecular abnormalities in childhood acute lymphoblastic leukaemia. Br J Haematol. 1997;98:134-139.
40. Nishimura R, Niida Y, Saikawa Y, et al. Microsatellite analysis of childhood leukemia: correlation of 9p and 12p chromosome abnormalities with expression of related genes. Pediatr Int. 1999;41:346-352.
41. Ford AM, Pombo-de-Oliveira MS, McCarthy KP, et al. Monoclonal origin of concordant T-cell malignancy in identical twins. Blood. 1997;89:281-285.
42. Fialkow PJ, Singer JW, Raskind WH, et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med. 1987;317:468-473.
43. Miyamoto T, Nagafuji K, Akashi K, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood. 1996;87:4789-4796.
44. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A. 2000;97:7521-7526.
45. Dworzak MN, Fritsch G, Fleischer C, et al. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow. Leukemia. 1997;11:1266-1273.
46. Greaves MF, Hariri G, Newman RA, Sutherland DR, Ritter MA, Ritz J. Selective expression of the common acute lymphoblastic leukemia (gp100) antigen on immature lymphoid cells and their malignant counterparts. Blood. 1983;61:628-639.
47. Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96:1094-1099.
48. Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJ. Field cancerization: why late "recurrent" ovarian cancer is not recurrent. Am J Obstet Gynecol. 1998;178:641-649.
49. McCann J. Unexpected late relapses seen in testicular cancer. J Natl Cancer Inst. 1998;90:1692-1693.
50. Aissani B, Bonan C, Baccichet A, Sinnett D. Childhood acute lymphoblastic leukemia: is there a tumor suppressor gene in chromosome 12p12.3? Leuk Lymphoma. 1999;34:231-239.
51. VBASE directory of human genes. MRC Centre for Protein Engineering Web site. Available at: http://www.mcr-cpe.cam.ac.uk/imt-doc. Accessed March 1, 2001.
52. BLAST sequence similarity searching tool. National Library of Medicine Web site. Available at: http://www.ncbi.nlm.nih.gov/BLAST. Accessed March 1, 2001.